Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1/2 study of EV101 alone or in combination with clomiphene and concurrently with temozolomide for the treatment of patients suffering from recurrent or progressive glioblastoma

Next Previous
Trial Profile

A phase 1/2 study of EV101 alone or in combination with clomiphene and concurrently with temozolomide for the treatment of patients suffering from recurrent or progressive glioblastoma

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 13 Jul 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clomifene (Primary) ; EV 101 (Primary) ; Temozolomide (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 08 Jul 2021 According to an Enveric Biosciences media release, first patient is expected to be enrolled in the fourth quarter of 2021.
  • 08 Jul 2021 According to an Enveric Biosciences media release, the company has received approval from the Israeli Ministry of Health to begin this study. The study will be conducted at the Davidoff Institute of Oncology, Rabin Medical Center, in Israel and Dr. Tali Siegal will be the principal investigator.
  • 22 Jan 2021 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top